Indianapolis Colts Coach Back On the Sidelines After Leukemia Treatment

Three months after he received a diagnosis of leukemia that demanded immediate treatment, Indianapolis Colts head coach Chuck Pagano has returned to take the helm of his team, just prior to the final weekend of the National Football League's regular season.

In his absence, the Colts have been spectacular, winning nine of their previous 12 games, thanks in part to rookie sensation Andrew Luck.

The Colts secured a playoff spot prior to this weekend's game against the Houston Texans.

Pagano's diagnosis of acute promyelocytic leukemia—an aggressive subtype that, if untreated, can be fatal within a matter of months—hit the news on October 1.

The rookie coach then underwent three rounds of chemotherapy. About five weeks later, in between rounds one and two, the team announced that Pagano was in remission.

Said coach Pagano yesterday:

"I told you my best day of my life was [my wedding date]. Today was No. 2. Getting to pull up, drive in, get out of my car, the key fob still worked. I was beginning to question whether it would or not. When I asked for Bruce to take over, I asked for him to kick some you-know-what and to do great. Damn Bruce, you had to go and win nine games? Tough act to follow. Tough act to follow. Best in the history of the NFL. That's what I have to come back to."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap